Home › Research › Treatments
Lecanemab como tratamiento en el deterioro cognitivo de pacientes con Alzheimer
Stephanie Hernández Durán, Militza Jakeline Gómez Ceja. Acta Médica Grupo Ángeles, 2025-01-01
Topic: Risk, prevention and care in population studies
Introducción: la enfermedad de Alzheimer (EA) se define como un trastorno neurodegenerativo caracterizado por acumulación de placas beta amiloide a nivel cerebral, lo cual ocasiona alteraciones histopatológicas y se manifiesta, principalmente, en el deterioro cognitivo (DC).Objetivo: evaluar el efecto de lecanemab sobre el DC en pacientes con EA.Material y métodos: metaanálisis de artículos originales que evaluaron el DC durante los periodos de intervención con placebo y lecanemab.Resultados: la muestra global incluyó 5,069 sujetos.El tiempo de intervención fue de 12 y 18 meses, administrando dosis de 10 mg/kg de lecanemab cada dos semanas.Conclusión: se demostró que una dosis de 10 mg/kg reduce de manera significativa el DC en pacientes con EA, observándose resultados más favorables a 18 meses en comparación con los 12 meses de tratamiento.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Durán, S. H., & Ceja, M. J. G. (2025). Lecanemab como tratamiento en el deterioro cognitivo de pacientes con Alzheimer. Acta Médica Grupo Ángeles. https://doi.org/10.35366/119479
Vancouver
Durán SH, Ceja MJG. Lecanemab como tratamiento en el deterioro cognitivo de pacientes con Alzheimer. Acta Médica Grupo Ángeles. 2025. doi:10.35366/119479.
BibTeX
@article{duran2025-d42e1b7d,
author = {Durán, Stephanie Hernández and Ceja, Militza Jakeline Gómez},
title = {{Lecanemab como tratamiento en el deterioro cognitivo de pacientes con Alzheimer}},
journal = {Acta Médica Grupo Ángeles},
year = {2025},
doi = {10.35366/119479},
url = {https://doi.org/10.35366/119479}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Introducción: la enfermedad de Alzheimer (EA) se define como un trastorno neurodegenerativo caracterizado por acumulación de placas beta amiloide a nivel cerebral, lo cual ocasiona alteraciones histopatológicas y se manifiesta, principalmente, en el deterioro cognitivo (DC).Objetivo: evaluar el efecto de lecanemab sobre el DC en pacientes con EA.Material y métodos: metaanálisis de artículos originales que evaluaron el DC durante los periodos de intervención con placebo y lecanemab.Resultados: la muestra global incluyó 5,069 sujetos.El tiempo de intervención fue de 12 y 18 meses, administrando dosis de 10 mg/kg de lecanemab cada dos semanas.Conclusión: se demostró que una dosis de 10 mg/kg reduce de manera significativa el DC en pacientes con EA, observándose resultados más favorables a 18 meses en comparación con los 12 meses de tratamiento.
Why it matters
This meta-analysis of 5,069 subjects found that lecanemab 10 mg/kg every two weeks significantly reduced cognitive decline in patients with Alzheimer disease, with more favourable results at 18 months than at 12 months. It supports lecanemab as a treatment for cognitive decline in these patients.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 27/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record and institution's track record, so those were left out: it earned 25 of the 93 points we could judge it on, which is 27 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Acta Médica Grupo Ángeles) |
| Journal's citation record | 0 / 4 | Acta Médica Grupo Ángeles: journal h-index 10 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Militza Jakeline Gómez Ceja holds only 1 work(s), too few to judge a track record — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 25 / 93 | Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 25 of the 93 points we could judge it on is 27 out of 100. |
| Total | 27 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Treatments
Also tagged “double-blind”
783 studies in the library carry the topic tag “double-blind”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.